Total Payments
$89,956
2024 Payments
$68,147
Companies
48
Transactions
339
Medicare Patients
4,190
Medicare Billing
$406,545
Payment Breakdown by Category
Research$72,649 (80.8%)
Food & Beverage$6,457 (7.2%)
Consulting$5,841 (6.5%)
Travel$4,989 (5.5%)
Gifts$20.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $72,649 | 19 | 80.8% |
| Food and Beverage | $6,457 | 290 | 7.2% |
| Consulting Fee | $5,841 | 5 | 6.5% |
| Travel and Lodging | $4,989 | 24 | 5.5% |
| Gift | $20.00 | 1 | 0.0% |
Payments by Type
Research
$72,649
19 transactions
General
$17,307
320 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $66,015 | 3 | $0 (2024) |
| PFIZER INC. | $13,403 | 28 | $0 (2023) |
| Novo Nordisk AS | $1,671 | 6 | $0 (2018) |
| Regeneron Pharmaceuticals, Inc. | $1,606 | 13 | $0 (2024) |
| Ferring International Pharmascience Center US | $1,227 | 15 | $0 (2017) |
| ModernaTX, Inc. | $1,226 | 10 | $0 (2024) |
| Merck Sharp & Dohme LLC | $978.79 | 28 | $0 (2024) |
| Novo Nordisk Inc | $478.02 | 27 | $0 (2024) |
| Amgen Inc. | $438.85 | 30 | $0 (2024) |
| ABBVIE INC. | $436.61 | 27 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $68,147 | 59 | Eli Lilly and Company ($64,625) |
| 2023 | $12,807 | 39 | PFIZER INC. ($10,912) |
| 2022 | $543.04 | 31 | Novo Nordisk Inc ($117.00) |
| 2021 | $698.79 | 47 | AbbVie Inc. ($157.06) |
| 2020 | $410.97 | 28 | Amgen Inc. ($75.09) |
| 2019 | $1,823 | 39 | PFIZER INC. ($1,342) |
| 2018 | $2,846 | 49 | Novo Nordisk AS ($1,671) |
| 2017 | $2,681 | 47 | Ferring International Pharmascience Center US ($1,227) |
All Payment Transactions
339 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Endo USA, Inc. | AVEED (Biological) | Food and Beverage | In-kind items and services | $18.84 | General |
| Category: UROLOGY | ||||||
| 12/11/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $17.91 | General |
| Category: UROLOGY | ||||||
| 11/20/2024 | Merck Sharp & Dohme LLC | GARDASIL (Biological), CAPVAXIVE, GARDASIL 9 | Food and Beverage | In-kind items and services | $15.69 | General |
| Category: VACCINE | ||||||
| 11/06/2024 | ABBVIE INC. | LINZESS (Drug), VIBERZI, CREON | Food and Beverage | In-kind items and services | $27.03 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/10/2024 | Medline Industries LP | — | Food and Beverage | In-kind items and services | $32.85 | General |
| 10/09/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $17.33 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $63,117.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $1,508.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | ||||||
| 09/18/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $16.18 | General |
| Category: Respiratory | ||||||
| 09/14/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $288.96 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $265.53 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $240.00 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $120.00 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Travel and Lodging | Cash or cash equivalent | $89.72 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $81.00 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $45.00 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | Cash or cash equivalent | $35.82 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $30.00 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $30.00 | General |
| 09/11/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.54 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/04/2024 | Medtronic, Inc. | INTELLIS ADAPTIVESTIM (Device) | Food and Beverage | In-kind items and services | $16.02 | General |
| Category: Spinal Cord Neurostimulation | ||||||
| 08/28/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $21.90 | General |
| Category: Diabetes | ||||||
| 08/21/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $14.44 | General |
| Category: Biological | ||||||
| 08/19/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $31.03 | Research |
| Study: A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | ||||||
| 08/19/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $28.77 | Research |
| Study: A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | Eli Lilly and Company | $63,117 | 1 |
| A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | PFIZER INC. | $5,027 | 3 |
| A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity | Regeneron Pharmaceuticals, Inc. | $1,606 | 13 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | Eli Lilly and Company | $1,508 | 1 |
| A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | Eli Lilly and Company | $1,390 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 920 | 1,446 | $192,627 | $85,575 |
| 2022 | 23 | 1,088 | 3,042 | $262,387 | $124,731 |
| 2021 | 24 | 1,297 | 3,017 | $263,059 | $124,755 |
| 2020 | 15 | 885 | 1,373 | $186,618 | $71,484 |
Total Patients
4,190
Total Services
8,878
Medicare Billing
$406,545
Procedure Codes
80
All Medicare Procedures & Services
80 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 182 | 421 | $89,673 | $34,272 | 38.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 153 | 153 | $34,425 | $18,686 | 54.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 103 | 156 | $22,464 | $8,529 | 38.0% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 81 | 81 | $7,275 | $6,135 | 84.3% |
| 91320 | Sarscv2 vac 30mcg trs-suc im | Office | 2023 | 41 | 41 | $7,175 | $5,268 | 73.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 84 | 84 | $3,864 | $2,450 | 63.4% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2023 | 14 | 14 | $4,718 | $2,189 | 46.4% |
| 90480 | Admn sarscov2 vacc 1 dose | Office | 2023 | 56 | 56 | $4,480 | $2,178 | 48.6% |
| 91322 | Sarscov2 vac 50 mcg/0.5ml im | Office | 2023 | 15 | 15 | $2,625 | $2,145 | 81.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 25 | 134 | $6,164 | $1,232 | 20.0% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 12 | 16 | $1,712 | $628.48 | 36.7% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 17 | 42 | $2,184 | $605.50 | 27.7% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 12 | 12 | $1,800 | $425.52 | 23.6% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 21 | 32 | $480.00 | $304.64 | 63.5% |
| 90471 | Administration of vaccine | Office | 2023 | 21 | 23 | $1,078 | $256.02 | 23.7% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 51 | 51 | $280.44 | $121.61 | 43.4% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 13 | 90 | $1,980 | $94.54 | 4.8% |
| 81003 | Automated urinalysis test | Office | 2023 | 19 | 25 | $250.00 | $55.00 | 22.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 203 | 525 | $111,825 | $42,797 | 38.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 12 | 1,320 | $36,960 | $22,368 | 60.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 167 | 167 | $37,575 | $20,979 | 55.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 115 | 178 | $25,632 | $10,083 | 39.3% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 107 | 108 | $8,100 | $7,583 | 93.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 110 | 111 | $5,106 | $3,113 | 61.0% |
| 0241U | Respiratory infectious agent detection by rna for severe acute respiratory syndrome coronavirus 2 (covid 19), influenza a, influenza b, and respiratory syncytial virus, upper respiratory specimen, each reported as detected or not detected | Office | 2022 | 18 | 21 | $3,780 | $2,958 | 78.3% |
About Dr. John Rubino, MD
Dr. John Rubino, MD is a Internal Medicine healthcare provider based in Raleigh, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/09/2007. The National Provider Identifier (NPI) number assigned to this provider is 1962543280.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Rubino, MD has received a total of $89,956 in payments from pharmaceutical and medical device companies, with $68,147 received in 2024. These payments were reported across 339 transactions from 48 companies. The most common payment nature is "" ($72,649).
As a Medicare-enrolled provider, Rubino has provided services to 4,190 Medicare beneficiaries, totaling 8,878 services with total Medicare billing of $406,545. Data is available for 4 years (2020–2023), covering 80 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Raleigh, NC
- Active Since 02/09/2007
- Last Updated 01/29/2009
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1962543280
Products in Payments
- ZAVZPRET (Drug) $5,027
- V160 (Biological) $727.09
- JARDIANCE (Drug) $248.37
- FARXIGA (Drug) $244.55
- UBRELVY (Drug) $189.98
- Ozempic (Drug) $163.69
- Aimovig (Biological) $136.19
- JANUVIA (Drug) $125.77
- Rybelsus (Drug) $123.61
- Otezla (Drug) $113.77
- QULIPTA (Drug) $111.07
- ENTRESTO (Drug) $105.71
- EVENITY (Biological) $100.41
- Saxenda (Drug) $96.51
- XARELTO (Drug) $86.83
- Wegovy (Drug) $81.12
- Prolia (Biological) $77.26
- Vascepa (Drug) $76.90
- XIFAXAN (Drug) $63.91
- Veozah (Drug) $58.58
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Raleigh
Dr. Ravish Sachar, M.d, M.D
Internal Medicine — Payments: $1.8M
Internal Medicine $1.8M
Dr. Wayne Harper, M.d, M.D
Internal Medicine — Payments: $584,073
Internal Medicine $584,073
Charles Cook, M. D, M. D
Internal Medicine — Payments: $454,802
Internal Medicine $454,802
Dr. Christina Crater, M.d, M.D
Internal Medicine — Payments: $330,450
Internal Medicine $330,450
Kevin Manocha, Md, MD
Internal Medicine — Payments: $142,893
Internal Medicine $142,893
Dr. Islam Othman, M.d, M.D
Internal Medicine — Payments: $77,969
Internal Medicine $77,969